Adovate
- Biotech or pharma, therapeutic R&D
Adovate is a clinical-stage pharmaceutical company developing best-in-class adenosine receptor antagonists for asthma, cancer, and other inflammatory diseases. Our lead asset, ADO-5030, a selective A2B receptor antagonist, is in first-in-human trials for asthma, targeting all patient types, including steroid-resistant populations. Early toxicology showed strong safety even at supra-therapeutic doses, and Phase 2 proof-of-concept is on track. Adovate’s next-generation platform produces highly potent, selective molecules with improved biodistribution, overcoming historical challenges of adenosine-targeting drugs. Over $5M in non-dilutive grant funding has supported our development efforts. Led by Dr. Joel Linden, a world leader in adenosine biology, and Dr. Robert Thompson, a pioneer in adenosine medicinal chemistry, Adovate is seeking venture and corporate venture investors alongside a strategic partner to advance ADO-5030 and expand our platform across high-value therapeutic areas.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}